Drug Profile


Alternative Names: CP-424391; CP-424391-18; RQ-00000005; RQ-5

Latest Information Update: 04 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer RaQualia Pharma; Shire; University of Melbourne
  • Class Osteoporosis therapies; Pyrazolones; Small molecules
  • Mechanism of Action Ghrelin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Gastrointestinal disorders; Musculoskeletal disorders

Highest Development Phases

  • No development reported Gastrointestinal disorders; Musculoskeletal disorders

Most Recent Events

  • 04 Sep 2015 No recent reports on development identified - Phase-I for Gastrointestinal disorders in USA, Australia (PO)
  • 16 Feb 2011 Carpromorelin licensed to Shire AG for the treatment of gastrointestinal disorders in the US
  • 17 Jan 2007 Phase-I clinical trials in Gastro-oesophageal reflux in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top